See more : Yunhong International (ZGYHU) Income Statement Analysis – Financial Results
Complete financial analysis of Acumen Pharmaceuticals, Inc. (ABOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acumen Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- ASE Technology Holding Co., Ltd. (ASX) Income Statement Analysis – Financial Results
- Technip Energies N.V. (THNPY) Income Statement Analysis – Financial Results
- Ester Industries Limited (ESTER.NS) Income Statement Analysis – Financial Results
- Wise plc (GB00BL9YR756.SG) Income Statement Analysis – Financial Results
- BlackRock Income and Growth Investment Trust plc (BRIG.L) Income Statement Analysis – Financial Results
Acumen Pharmaceuticals, Inc. (ABOS)
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 1.44M | 1.70M |
Cost of Revenue | 42.32M | 169.00K | 4.00K | 8.00K | 8.58K |
Gross Profit | -42.32M | -169.00K | -4.00K | 1.43M | 1.69M |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 99.44% | 99.49% |
Research & Development | 42.32M | 32.36M | 12.31M | 8.00M | 8.58M |
General & Administrative | 18.82M | 12.88M | 7.28M | 1.35M | 926.00K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 18.82M | 12.88M | 7.28M | 1.35M | 926.00K |
Other Expenses | 0.00 | -11.00K | 51.00K | 0.00 | 0.00 |
Operating Expenses | 61.14M | 45.24M | 19.58M | 9.35M | 9.50M |
Cost & Expenses | 61.14M | 45.24M | 19.58M | 9.35M | 9.50M |
Interest Income | 10.21M | 2.39M | 84.00K | 1.00K | 45.00K |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | |
Depreciation & Amortization | 184.00K | 169.00K | 4.00K | 7.91M | 7.81M |
EBITDA | -51.61M | -42.69M | 61.58M | 587.00K | 119.00K |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | -591.78% | -451.27% |
Operating Income | -61.14M | -45.24M | 61.57M | -7.91M | -7.81M |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | -550.97% | -459.93% |
Total Other Income/Expenses | 8.77M | 2.38M | -81.02M | 587.00K | -102.00K |
Income Before Tax | -52.37M | -42.86M | -100.61M | -7.33M | -7.91M |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -510.10% | -465.94% |
Income Tax Expense | 0.00 | -2.38M | 81.07M | -1.00K | -45.00K |
Net Income | -52.37M | -40.48M | -181.68M | -7.32M | -7.86M |
Net Income Ratio | 0.00% | 0.00% | 0.00% | -510.03% | -463.29% |
EPS | -1.08 | -1.00 | -4.49 | -0.18 | -0.20 |
EPS Diluted | -1.08 | -1.00 | -4.49 | -0.18 | -0.20 |
Weighted Avg Shares Out | 48.49M | 40.60M | 40.47M | 40.15M | 40.15M |
Weighted Avg Shares Out (Dil) | 48.61M | 40.60M | 40.47M | 40.15M | 40.15M |
4 Alzheimer's Penny Stocks To Watch After Biogen Stock Explodes
Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q2 2022 Results - Earnings Call Transcript
Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022
Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q1 2022 Results - Earnings Call Transcript
AANA-VirtaMed Collaboration Incorporates Learning Initiative into Virtual Training
Acumen Pharmaceuticals to Report First Quarter 2022 Financial Results on May 16, 2022
Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q4 2021 Results - Earnings Call Transcript
Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022
Cazoo übernimmt führenden italienischen Online-Autohändler brumbrum
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index
Source: https://incomestatements.info
Category: Stock Reports